SynthesisOpen heart2023
Role of genetic polymorphisms in clopidogrel response variability: a systematic review.
Synthesis in Open heart, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Antiplatelet Therapy in Patients Receiving Percutaneous Coronary Intervention for Bifurcation Lesions.Korean circulation journal · 2026Review
- Modern Era in Personalized Medicine of Dual Antiplatelet Therapy After Myocardial Revascularization.Journal of clinical medicine · 2026Review
- Association of a platelet function testing-guided intensified antiplatelet strategy with thromboembolic events after EP2 stent-assisted coil embolization in patients with unruptured intracranial aneurysms.Frontiers in neurology · 2026Article
- Fibrinogen and catheter advancement difficulty: unveiling the key predictors of earlyFrontiers in medicine · 2026Article
- Long-term outcome of tailored antithrombotic therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a 5-year retrospective cohort study.Heart and vessels · 2026Article
- Article
- P2YBiomedicines · 2025Article
- CYP2C19 Polymorphism and Clopidogrel Efficacy in Long-Term Outcomes of Large-Artery Atherosclerotic Stroke: The NCVC Genome Registry.JACC. Asia · 2025Article
- Beyond CYP2C19: inflammation and angiogenesis gene variants drive clopidogrel resistance in CAD patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Article
- A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.NPJ genomic medicine · 2025Review
- Evaluation of clopidogrel responsiveness using the Platelet Function Analyzer-200 (PFA-200) in dogs.Frontiers in veterinary science · 2025Article
- Proton pump inhibitors and cardiovascular risk: a critical review.Future cardiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionClopidogrel is a P2Y AREAS COVERED: As a prodrug, the metabolism and efficacy of clopidogrel are contingent on the presence of wild-type CYP450 (CYP2C19) alleles. Genetic polymorphisms and variants are well known to impair its ability to prevent major adverse cardiovascular events in these patients, with inadequate response rates as high as 30% in previous publications. Patterns of allelic frequencies are expected to exhibit similarities between individuals of the same ancestry, ethnic group or geographic region. Accordingly, we seek to further elucidate worldwide prevalence rates for genetic polymorphisms in the CYP2C19-dependent metabolism of clopidogrel and review the potential of personalised CYP2C19 genotyping in clinical practice to mitigate this high treatment resistance and its associated burden on patients. EXPERTS' COMMENTARY: Our findings support the consideration of genotyping before initiation of therapy to guide adequate dosage or substitutions of other P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.